Linzess Launch Off To A Strong Start, Say Ironwood And Forest
This article was originally published in The Pink Sheet Daily
After a December launch of the constipation treatment Linzess, Ironwood and Forest discuss how the drug has been doing since hitting the market at a recent health care conference.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.